Ceritinib – Potent Second-Generation ALK Inhibitor Targeted Therapy
Ceritinib is an oral, highly selective, and potent second-generation small-molecule anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, engineered for the systemic targeted therapy of solid tumors. The mechanism of action of ceritinib involves blocking the autophosphorylation of the ALK kinase domain, resulting in the complete suppression of downstream signaling pathways such as STAT3, PI3K/AKT/mTOR, and MAPK/ERK. This effectively disrupts proliferation and induces apoptosis in tumor cells expressing ALK fusion proteins or mutant forms of the kinase. The core pharmacological feature of ceritinib is its ability to overcome resistance to first-generation ALK inhibitors (specifically crizotinib) mediated by secondary mutations within the kinase domain. Additionally, ceritinib inhibits the insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1 proto-oncogene with minimal inhibition of off-target kinases.
The clinical uniqueness of ceritinib lies in its excellent ability to penetrate the blood-brain barrier and achieve high therapeutic concentrations within central nervous system tissues, enabling deep and durable intracranial responses in patients with metastatic brain lesions. The drug demonstrates high bioavailability, though its absorption is significantly affected by food intake. Peak plasma exposure is achieved within a median of 4 to 6 hours post-dose. Ceritinib is extensively bound to human plasma proteins (approximately 97%) and is primarily metabolized in the liver via the CYP3A4 isoenzyme through oxidative and dealkylation pathways. The mean elimination half-life ranges from approximately 31 to 41 hours, providing stable systemic exposure. Systemic clearance occurs predominantly through the intestines in the feces, with a minor fraction cleared via the kidneys in the urine.
The drug is administered orally. Initiating therapy requires mandatory prior molecular-genetic confirmation of the presence of an ALK gene rearrangement. Ongoing treatment necessitates regular monitoring of hepatic function, blood glucose levels, serum electrolytes, electrocardiograms, and serum amylase/lipase levels.
Indications
Ceritinib is indicated as a systemic targeted monotherapy for adult patients presenting with the following malignant neoplasm:
- Non-Small Cell Lung Cancer (NSCLC): treatment of adult patients with locally advanced or metastatic non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangements (ALK-positive NSCLC), either as first-line therapy or following disease progression on prior crizotinib therapy.
Dosage and administration
The dosing regimen of ceritinib requires strict adherence to co-administration guidelines with food and individual dose modifications based on treatment-related toxicities.
- Standard Therapeutic Dose: the recommended therapeutic dose is 450 mg taken orally once daily. The drug must be taken daily, at approximately the same time each day.
- Food Co-administration: the drug must be taken with food (ranging from a light snack to a full meal). It has been clinically established that administering 450 mg with food provides equivalent systemic exposure while significantly improving gastrointestinal tolerability compared to the former regimen of 750 mg taken under fasted conditions.
- Administration Method: capsules or tablets are taken orally, must be swallowed whole, and washed down with a glass of water. Opening, breaking, crushing, or chewing the medicinal product during handling is strictly prohibited.
- Missed Dose: if a scheduled dose is delayed by less than 12 hours, the patient must take the missed dose immediately and resume the regular schedule. If the delay exceeds 12 hours, that dose must be skipped entirely, and the patient returns to the planned routine. Taking a double dose on the following day is strictly prohibited. If vomiting occurs after taking a dose, a repeat capsule must not be administered on that day.
- Dose Modification for Toxicity: if severe adverse reactions develop (such as prominent hepatotoxicity, severe diarrhea, hyperglycemia, or QTc interval prolongation), therapy must be temporarily withheld. Upon clinical resolution of symptoms, treatment is resumed with step-down dose reductions of 150 mg: first to 300 mg once daily, then to 150 mg once daily. If a patient cannot tolerate 150 mg once daily, the drug must be permanently discontinued.
